Филтриране по Last updated date SelectСледПредиFrom - To Дата Крайна дата This week This month Last week Last month Category HumanCorporateVeterinaryHerbal Topic MedicinesCOVID-19PharmacovigilanceVaccinesReferralsPaediatricsRare diseasesRegulatory and procedural guidanceClinical trialsAdvanced therapiesData on medicinesCompliance and inspectionsInnovationResearch and developmentMedicine shortagesBiosimilarsSMEAntimicrobial resistanceGovernanceBrexitQuality of medicinesCorporateGeneric and hybrid medicinesEarly accessMedicines for use outside the EUFeesProduct informationScientific adviceMedical devicesMaximum residue limitMpoxBiologicalsScientific guidelinesVeterinary limited marketsCompassionate useCareersMedication errorParallel distributionPRIMEProcurement Diseases area Viral diseasesCancerImmune-system diseasesDiabetesNeurodegenerative diseasesCardiovascular diseasesHIV and AIDS Responsible body CHMP CVMP PRAC Management Board COMP PDCO CMDh HMPC CAT Patient safety Yes Leave this field blank Filter Резултати (3799) Sort by Last update date (new to old)Last update date (old to new)A-ZZ-A Leave this field blank Human medicines: highlights of 2021 15 February 2022NewsHumanMedicines Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7 - 10 February 2022 11 February 2022NewsHumanCOVID-19PharmacovigilanceReferralsVaccines PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market 11 February 2022NewsHumanReferrals EMA starts safety review of Janus kinase inhibitors for inflammatory disorders 11 February 2022NewsHumanReferrals Initiation of DARWIN EU® Coordination Centre advances integration of real-world evidence into assessment of medicines in the EU 9 February 2022NewsHumanData on medicines EMA evaluating data on booster dose of COVID-19 vaccine Comirnaty in adolescents 8 February 2022NewsHumanCOVID-19Vaccines Public consultation on reflection paper on prophylactic use of antimicrobials in animals 8 February 2022NewsVeterinaryAntimicrobial resistance A stronger role for EMA 31 January 2022NewsCorporate New gene therapy treatment for patients with relapsed or refractory large B-cell lymphoma 28 January 2022NewsHumanMedicines COVID-19: EMA recommends conditional marketing authorisation for Paxlovid 28 January 2022NewsHumanCOVID-19Medicines 1 … 46 47 48 49 50 Page 50 of 380 51 52 53 54 … 380
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7 - 10 February 2022 11 February 2022NewsHumanCOVID-19PharmacovigilanceReferralsVaccines
PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market 11 February 2022NewsHumanReferrals
EMA starts safety review of Janus kinase inhibitors for inflammatory disorders 11 February 2022NewsHumanReferrals
Initiation of DARWIN EU® Coordination Centre advances integration of real-world evidence into assessment of medicines in the EU 9 February 2022NewsHumanData on medicines
EMA evaluating data on booster dose of COVID-19 vaccine Comirnaty in adolescents 8 February 2022NewsHumanCOVID-19Vaccines
Public consultation on reflection paper on prophylactic use of antimicrobials in animals 8 February 2022NewsVeterinaryAntimicrobial resistance
New gene therapy treatment for patients with relapsed or refractory large B-cell lymphoma 28 January 2022NewsHumanMedicines
COVID-19: EMA recommends conditional marketing authorisation for Paxlovid 28 January 2022NewsHumanCOVID-19Medicines